Role of Efficacy Data in Selecting Optimal Therapy for Patients With Relapsed/Refractory CLL
Centering conversation on patients with relapsed/refractory chronic lymphocytic leukemia, Andrew Lipsky, MD, reviews efficacy data and considers how it impacts treatment selection.
EP: 1.Case Overview: Relapsed/Refractory CLL Treated With a BTK Inhibitor
EP: 2.Chronic Lymphocytic Leukemia: First-Line Treatment Armamentarium
EP: 3.Role of BTK Inhibitors as Second-Line Therapy for Patients With CLL
EP: 4.Clinical Trial Data in Relapsed/Refractory CLL: The ALPINE Trial
EP: 5.Clinical Trial Data in Relapsed/Refractory CLL: The ELEVATE-RR Trial
EP: 6.Role of Efficacy Data in Selecting Optimal Therapy for Patients With Relapsed/Refractory CLL
EP: 7.Relapsed/Refractory CLL: CV Safety Data With Available Therapies
Transcript:
Andrew H. Lipsky, MD: I think the progression-free survival is an incredibly meaningful end point for clinical trials in CLL [chronic lymphocytic leukemia]. To some extent, this reflects a consequence of our success in treating the disease. If you think about the median age of CLL patients, giving them more time on therapy with a limited number of side effects and good quality of life, that’s a really meaningful improvement in their overall ability to live with the disease. When it comes to overall survival benefits, those have been seen in comparisons of head-to-head trials of BTK [Bruton tyrosine kinase] inhibition to chemoimmunotherapy, and that demonstrates how far we’ve come in treating CLL. And that underlies the rationale for me that we really shouldn’t be giving chemoimmunotherapy anymore when treating this disease.
Transcript edited for clarity.
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
